Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

BACKGROUND: Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population. We tested whether interleukin-1β (IL-1β) blockade using canak...

Descripción completa

Detalles Bibliográficos
Autores principales: Hepprich, Matthias, Mudry, Jonathan M., Gregoriano, Claudia, Jornayvaz, Francois R., Carballo, Sebastian, Wojtusciszyn, Anne, Bart, Pierre-Alexandre, Chiche, Jean-Daniel, Fischli, Stefan, Baumgartner, Thomas, Cavelti-Weder, Claudia, Braun, Dominique L., Günthard, Huldrych F., Beuschlein, Felix, Conen, Anna, West, Emily, Isenring, Egon, Zechmann, Stefan, Bucklar, Gabriela, Aubry, Yoann, Dey, Ludovic, Müller, Beat, Hunziker, Patrick, Schütz, Philipp, Cattaneo, Marco, Donath, Marc Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481336/
https://www.ncbi.nlm.nih.gov/pubmed/36128334
http://dx.doi.org/10.1016/j.eclinm.2022.101649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481336/
https://www.ncbi.nlm.nih.gov/pubmed/36128334
http://dx.doi.org/10.1016/j.eclinm.2022.101649

Ejemplares similares